Focus Diagnostics expands launch of H1N1 test to CLIA labs
This article was originally published in Clinica
Executive Summary
Focus Diagnostics has made its H1N1 pandemic flu test available to other US labs with CLIA certification. The Cypress, California company is also "assessing its options" for marketing the Influenza A H1N1 (2009) Real Time RT-PCR test outside the US. The US FDA granted emergency use authorisation (EUA) for the diagnostic in July, making it the first commercially available H1N1 test. On August 17, the agency informed Focus – a subsidiary of Quest Diagnostics – that it had amended the EUA for the test. It now states that the test may be performed in labs certified under the US CLIA act to perform high-complexity tests and operate certain equipment.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.